Abstract:As the sentinels of the immune system, dendritic cells (DCs) play a critical role in initiating and regulating antigen-specific immune responses. Cross-priming, a process that DCs activate CD8 T cells by cross-presenting exogenous antigens onto their MHCI (Major Histocompatibility Complex class I), plays a critical role in mediating CD8 T cell immunity as well as tolerance. Current DC vaccines have remained largely unsuccessful despite their ability to potentiate both effector and memory CD8 T cell responses. There are two major hurdles for the success of DC-based vaccines: tumor-mediated immunosuppression and the functional limitation of the commonly used monocyte-derived dendritic cells (MoDCs). Due to their resistance to tumor-mediated suppression as inert vesicles, DC-derived exosomes (DCexos) have garnered much interest as cell-free therapeutic agents. However, current DCexo clinical trials have shown limited clinical benefits and failed to generate antigen-specific T cell responses. Another exciting development is the use of naturally circulating DCs instead of in vitro cultured DCs, as clinical trials with both human blood cDC2s (type 2 conventional DCs) and plasmacytoid DCs (pDCs) have shown promising results. pDC vaccines were particularly encouraging, especially in light of promising data from a recent clinical trial using a human pDC cell line, despite pDCs being considered tolerogenic and playing a suppressive role in tumors. However, how pDCs generate anti-tumor CD8 T cell immunity remains poorly understood, thus hindering their clinical advance. Using a pDC-targeted vaccine model, we have recently reported that while pDC-targeted vaccines led to strong cross-priming and durable CD8 T cell immunity, cross-presenting pDCs required cDCs to achieve cross-priming in vivo by transferring antigens to cDCs. Antigen transfer from pDCs to bystander cDCs was mediated by pDC-derived exosomes (pDCexos), which similarly required cDCs for cross-priming of antigen-specific CD8 T cells. pDCexos thus represent a new addition in our arsenal of DC-based cancer vaccines that would potentially combine the advantage of pDCs and DCexos.

Dendritic cells and tumor vaccine therapy

Progress on Dendritic Cell Vaccines in Tumor Immunotherapy

Anti-tumor Immunity with Dendritic Cells ( DC) Vaccine Modified by IL-18

Research of Dendritic Cell Tumor Vaccine

Dendritic Cells Based Immunotherapy

Dendritic cell biology and its role in tumor immunotherapy

Dendritic Cells and Their Role in Tumor Microenvironment

Dendritic Cells As Vectors for Immunotherapy of Tumor and Its Application for Gastric Cancer Therapy.

Advances in Research on Dendritic Cell-based Tumor Vaccine

Progress of Dendritic Cell in Tumor Immunotherapy

Study progress about dendritic/tumor fusion cell-based vaccine in tumor immunotherapy

Present Research on Dendritic Cells (DCs) Vaccine in Antitumor from Basic to Clinical Research

Impaired function of dendritic cells within the tumor microenvironment

Progress in Dendritic Cells Immunotherapy

DC-Based Vaccines for Cancer Immunotherapy

Applications and Advances of Dendritic Cells in Cancer Immunotherapy

Advances in dendritic cells-based for vaccine prostate cancer

Dendritic Cell-Based Vaccines Against Cancer: Challenges, Advances and Future Opportunities

The role of dendritic cells in cancer immunity and therapeutic strategies

Dendritic Cells Loaded with the Lysate of Tumor Cells Infected with Newcastle Disease Virus Trigger Potent Anti‑tumor Immunity by Promoting the Secretion of IFN‑γ and IL‑2 from T Cells

In Situ Dendritic Cell Vaccine for Effective Cancer Immunotherapy